about
Single amino acid substitutions in the chemotactic sequence of urokinase receptor modulate cell migration and invasionThe urokinase plasminogen activator and its receptor: role in cell growth and apoptosisRetro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.Urokinase receptor promotes ovarian cancer cell dissemination through its 84-95 sequence.Involvement of the soluble urokinase receptor in chondrosarcoma cell mobilization.Cyclization of the urokinase receptor-derived ser-arg-ser-arg-tyr Peptide generates a potent inhibitor of trans-endothelial migration of monocytes.A Macroscopic Mathematical Model for Cell Migration Assays Using a Real-Time Cell AnalysisIntegrin-dependent cell adhesion to neutrophil extracellular traps through engagement of fibronectin in neutrophil-like cellsMutant AKT1-E17K is oncogenic in lung epithelial cellsTGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction.The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells.Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors.The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling.AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency.The cross-talk between the urokinase receptor and fMLP receptors regulates the activity of the CXCR4 chemokine receptor.Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation.Cross-talk between fMLP and vitronectin receptors triggered by urokinase receptor-derived SRSRY peptide.Early vitronectin receptor downregulation in a melanoma cell line during all-trans retinoic acid-induced apoptosis.Effects of balloon injury on neointimal hyperplasia in streptozotocin-induced diabetes and in hyperinsulinemic nondiabetic pancreatic islet-transplanted rats.Inhibition of receptor-dependent urokinase signaling by specific Ser to Glu substitutions.Engaged urokinase receptors enhance tumor breast cell migration and invasion by upregulating alpha(v)beta5 vitronectin receptor cell surface expression.Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.Urokinase receptor derived peptides as potent inhibitors of the formyl peptide receptor type 1-triggered cell migration.Structure-based design of an urokinase-type plasminogen activator receptor-derived peptide inhibiting cell migration and lung metastasis.Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor Development.Treatment with a Urokinase Receptor-derived Cyclized Peptide Improves Experimental Colitis by Preventing Monocyte Recruitment and Macrophage PolarizationIn vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patientsIn vitro receptor imaging for characterization of human solid tumorsIn vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizerThe metastasis-associated 67-kDa laminin receptor is involved in G-CSF-induced hematopoietic stem cell mobilizationActivation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrinInvolvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilizationAntimicrobial human beta-defensin-2 stimulates migration, proliferation and tube formation of human umbilical vein endothelial cellsThe soluble form of urokinase receptor promotes angiogenesis through its Ser⁸⁸-Arg-Ser-Arg-Tyr⁹² chemotactic sequenceStructure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity
P50
Q27319474-FD85EE19-A9AD-4E2A-B7F8-9A7C62134254Q28235072-482A6B05-8F37-4ED3-BB86-AA252A2A6606Q33683537-895BF942-2BC0-4835-B0F4-B480EC18DE2BQ34100895-B61C72A6-3142-42C1-A71B-8875AAEA1341Q34495535-9F44BCD5-1061-48D0-AB02-31BDDB4BFD77Q35621562-72F9B196-03FA-43AC-B585-DCD7B5B67658Q36146797-537E2782-D3F5-47A8-AB28-1F966AC60A3EQ36271580-2F083B04-0358-4DAE-9E6F-BF0FDD23EF66Q36545440-835CB5F4-2736-4790-8BDF-92CA529F5F69Q36907085-AFB41809-5B93-46F6-9242-67D77FA8265DQ37688084-552C719A-5493-4185-A9EF-B11840C48D87Q37894751-FA788BE5-5BFB-446A-806F-3A188A8A9F99Q37895295-71EDF319-95B7-4940-A496-2C832A20E280Q38970503-8D46D00F-99FB-477B-BDDF-F3776DA3D6BAQ39007327-FF9BF2D1-F027-4808-990B-066790C2B61BQ39640346-0EC77EB2-4CB9-45EC-B735-BAB38F4AECA7Q39931019-8CF353C4-13CD-402C-A21D-7A45B7341EE8Q40428098-DCA5D778-2479-4C0F-824D-1D136BC2FC00Q40661911-C6ED13DD-C2C5-45FD-94FD-E9FFAB70CA3CQ43645326-C33239E1-1CE8-462D-9C72-8A7DA19DE393Q43944113-0D93CA14-690B-482D-9CD7-A7BD282D6FC1Q44226852-DE09FFA3-74E3-4DE3-AFF9-646533CEB9DAQ47140492-631EFC1B-EF09-4D44-BEE4-107F316B66F6Q47334054-9FCCF38D-EF27-4E13-8965-A7D33160B0FFQ50584784-02A6207F-9CAA-49AE-88F4-44B13A84E179Q53682448-5C61D2E2-B29C-4293-B25C-A14988A39BC4Q58883590-94658A18-CBC5-43EE-B1EF-86326162E216Q73041298-C6DBDFEB-7581-4153-9DCD-8FEBE7AAEB20Q73553656-82C4E179-70FC-4D10-A83E-7F959498C0C7Q79362744-603B3323-0549-45F5-B114-BE7396A5BC10Q79760684-826C524B-5B0A-4B48-8017-0BF09416C29FQ80043945-08D0F2BF-BFB0-4334-B617-27E1CBB4C7B7Q80884356-4D0A3371-8059-44CD-A63B-B2134677201CQ82765635-8A5FC2FB-FEC1-42D6-8CFC-0F5C549A24A9Q85110019-789ACF4C-E426-4CB9-AC39-963372E19862Q92757292-B4D0320F-D605-4647-8E8A-60AC059DABC9
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-9768-2997
@en
name
Maria Vincenza Carriero
@ast
Maria Vincenza Carriero
@en
Maria Vincenza Carriero
@es
Maria Vincenza Carriero
@nl
type
label
Maria Vincenza Carriero
@ast
Maria Vincenza Carriero
@en
Maria Vincenza Carriero
@es
Maria Vincenza Carriero
@nl
prefLabel
Maria Vincenza Carriero
@ast
Maria Vincenza Carriero
@en
Maria Vincenza Carriero
@es
Maria Vincenza Carriero
@nl
P106
P1153
6701534447
P21
P31
P496
0000-0002-9768-2997